| Ytd | -21.13% | |
| 1y | 64.71% |
| Open | 3.20 | Prev Close | 3.21 | Low | 3.17 | High | 3.37 | Mkt Cap | 732.14M |
| Vol | 2.38M | Avg Vol | 3.95M | EPS | -0.57 | P/E | N/A | Forward P/E | -9.74 |
| Beta | 2.48 | Short Ratio | 1.78 | Inst. Own | 75.69% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 3.44 | 200-d Avg | 4.16 | 1yr Est | 13.67 |
CTMX News
- Fast Track Designation follows encouraging Phase 1 data that were previously reported for R/R mCRC
AWM Investment Company Inc. acquired a new stake in CytomX Therapeutics, Inc. (NASDAQ: CTMX) during
JP Morgan analyst Anupam Rama maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and l
Bank of America Corp DE boosted its position in CytomX Therapeutics, Inc. (NASDAQ: CTMX) by 1,064.3%
CTMX has the PROBODY platform, which I think potentially unlocks difficult oncology targets by limit
Guggenheim analyst Michael Schmidt maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and low
CytomX Therapeutics, Inc. (CTMX) Q2 2026 Earnings Call Transcript
CytomX Therapeutics NASDAQ: CTMX said its second-quarter focus remained on advancing Varseta-M, an E
CytomX Therapeutics (CTMX) came out with a quarterly loss of $0.09 per share versus the Zacks Consen
CytomX Therapeutics (NASDAQ:CTMX) reported quarterly losses of $(0.09) per share which beat the anal
Varsetatug masetecan (“Varseta-M”) Program: - Phase 1 monotherapy update in advanced colorectal canc
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CT
SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CT
ADAR1 Capital Management LLC reduced its position in CytomX Therapeutics, Inc. (NASDAQ: CTMX) by 20.
SOUTH SAN FRANCISCO, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CT
CytomX Therapeutics (CTMX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism a
CytomX Therapeutics, Inc. (CTMX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference
- Expanded collaboration builds upon research momentum in developing next-generation bispecific immu
- Expanded collaboration builds upon research momentum in developing next-generation bispecific immu
In March, CTMX showcased Varseta-M's potential in late-line metastatic colorectal cancer, although t
SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTM
SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTM
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains CytomX Therapeutics (NASDAQ:CTMX) wi
CytomX Therapeutics, Inc. (CTMX) Q1 2026 Earnings Call Transcript
CytomX Therapeutics (CTMX) came out with a quarterly loss of $0.1 per share versus the Zacks Consens
CytomX Therapeutics (NASDAQ:CTMX) reported quarterly losses of $(0.10) per share which beat the anal
Piper Sandler analyst Joseph Catanzaro maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overwei
Barclays analyst Etzer Darout maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and r
Jefferies analyst Roger Song maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and raises th
CytomX stock falls after $250 million share sale, even as new colorectal cancer data shows strong re
Guggenheim analyst Michael Schmidt maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and rai
Wedbush analyst Robert Driscoll maintains CytomX Therapeutics (NASDAQ:CTMX) with a Outperform and
Common StockPreferred StockDebt SecuritiesWarrantsUnitsWe may offer and sell the securities identifi
In addition, CytomX expects to grant the underwriters a 30-day option to purchase up to an additiona
CytomX Therapeutics stock jumps in premarket trading after Phase 1 data for Varseta-M showed tumor r
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains CytomX Therapeutics (NASDAQ:CTMX) wi
JP Morgan analyst Anupam Rama upgrades CytomX Therapeutics (NASDAQ:CTMX) from Neutral to Overweig
Dow Jones index up 500 points; Nebius Group NV shares rise 12.7% on AI agreement with Meta Platforms
NBIS: 17% | Nebius Announced 5-Year $12B AI Infrastructure Agreement With Meta To Provide Dedicated
- Confirmed response rates in expansion cohorts of 32% at 10 mg/kg Q3W dose and 20% at 8.6 mg/kg Q3W
CytomX Therapeutics (NASDAQ:CTMX) reported quarterly losses of $(0.22) per share which missed the an
CytomX Therapeutics (CTMX) will release its Q4 earnings on March 16, with analysts expecting a loss
Guggenheim analyst Michael Schmidt reiterates CytomX Therapeutics (NASDAQ:CTMX) with a Buy and ma
Cantor Fitzgerald analyst Olivia Brayer maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overwe